Global Alpha-1 Lung Disease Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Alpha-1 Lung Disease Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
Alpha-1 Lung Disease report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Alpha-1 Lung Disease market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Specialty Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Alpha-1 Lung Disease industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Alpha-1 Lung Disease key companies include Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline and CSL Behring, etc. Pfizer, Baxter, AstraZeneca are top 3 players and held % share in total in 2022.
Alpha-1 Lung Disease can be divided into Augmentation Therapy, Cystic Fibrosis(CF), Non-CF Bronchiectasis(NCFB) and Other, etc. Augmentation Therapy is the mainstream product in the market, accounting for % share globally in 2022.
Alpha-1 Lung Disease is widely used in various fields, such as Hospitals, Specialty Clinics, Pharmacies and Others, etc. Hospitals provides greatest supports to the Alpha-1 Lung Disease industry development. In 2022, global % share of Alpha-1 Lung Disease went into Hospitals filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Alpha-1 Lung Disease market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Vertex Pharmaceuticals
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Kedrion Group
ProMetic Life Sciences
Segment by Type
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Hospitals
Specialty Clinics
Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Alpha-1 Lung Disease market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Alpha-1 Lung Disease introduction, etc. Alpha-1 Lung Disease Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Alpha-1 Lung Disease market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Alpha-1 Lung Disease report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Alpha-1 Lung Disease market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Specialty Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Alpha-1 Lung Disease industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Alpha-1 Lung Disease key companies include Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline and CSL Behring, etc. Pfizer, Baxter, AstraZeneca are top 3 players and held % share in total in 2022.
Alpha-1 Lung Disease can be divided into Augmentation Therapy, Cystic Fibrosis(CF), Non-CF Bronchiectasis(NCFB) and Other, etc. Augmentation Therapy is the mainstream product in the market, accounting for % share globally in 2022.
Alpha-1 Lung Disease is widely used in various fields, such as Hospitals, Specialty Clinics, Pharmacies and Others, etc. Hospitals provides greatest supports to the Alpha-1 Lung Disease industry development. In 2022, global % share of Alpha-1 Lung Disease went into Hospitals filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Alpha-1 Lung Disease market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Vertex Pharmaceuticals
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Kedrion Group
ProMetic Life Sciences
Segment by Type
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Segment by Application
Hospitals
Specialty Clinics
Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Alpha-1 Lung Disease market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Alpha-1 Lung Disease introduction, etc. Alpha-1 Lung Disease Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Alpha-1 Lung Disease market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices